PFE logo

Pfizer (PFE) Stock

Profile

Full Name:

Pfizer Inc.

Sector:

Healthcare

Country:

United States

IPO:

01 June 1972

Indexes:

Description:

Pfizer Inc. is one of the leading international biopharmaceutical companies, founded in New York in 1849. Every year, Pfizer's medicines and vaccines help people around the world fight many diseases and lead a healthy lifestyle. The company's product portfolio includes medicines, including vaccines, as well as well-known vitamins and other products that promote health maintenance. The IH segment focuses on the development and commercialization of medicines and vaccines for internal diseases, oncology, inflammation and immunology, morbidity, and healthcare. The EH segment is involved in the development and supply of proprietary generics, non-patented sterile injectable drugs, biosimilars, and certain proprietary products, including anti-infectives.

Key Details

Price

$26.26

TTM Dividend Yield

6.44%(+5.06% YoY)

Annual Revenue

$58.50 B(-41.70% YoY)

Annual EPS

$0.37(-93.24% YoY)

PE Ratio

35.66(-52.31% YoY)

Beta

0.21

Events Calendar

Earnings

Next earnings date:

May 01, 2025

Recent quarterly earnings:

Jan 17, 2025

Recent annual earnings:

Jan 17, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

Jan 24, 2025
Splits

Next split:

N/A

Recent split:

Nov 17, 2020

Analyst ratings

Recent major analysts updates

28 Jan '25 Citigroup
Neutral
08 Jan '25 UBS
Neutral
18 Dec '24 Truist Securities
Buy
11 Dec '24 Guggenheim
Buy
15 Nov '24 Wolfe Research
Underperform
25 Oct '24 Cantor Fitzgerald
Overweight
23 Oct '24 Cantor Fitzgerald
Overweight
17 Oct '24 Bernstein
Market Perform
03 Oct '24 Cantor Fitzgerald
Overweight
16 Sept '24 Cantor Fitzgerald
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Smaller US winter COVID wave adds pressure to Pfizer turnaround
Smaller US winter COVID wave adds pressure to Pfizer turnaround
Smaller US winter COVID wave adds pressure to Pfizer turnaround
PFE
reuters.com03 February 2025

Health experts are noticing that this winter, the number of COVID-19 cases in the U.S. is likely to be much lower than in past years. This situation may increase the pressure on Pfizer to boost its sales from treatments that are not related to COVID.

Pfizer resolves conservative challenge to diversity fellowship program
Pfizer resolves conservative challenge to diversity fellowship program
Pfizer resolves conservative challenge to diversity fellowship program
PFE
reuters.com31 January 2025

Pfizer has settled a lawsuit from a conservative organization that claimed the company's fellowship program, aimed at increasing the number of Black, Latino, and Native American leaders, unfairly discriminated against white and Asian-American applicants.

Pfizer (PFE) is a Top-Ranked Momentum Stock: Should You Buy?
Pfizer (PFE) is a Top-Ranked Momentum Stock: Should You Buy?
Pfizer (PFE) is a Top-Ranked Momentum Stock: Should You Buy?
PFE
zacks.com30 January 2025

Are you looking for ways to choose powerful stocks that can outperform the market for your investment portfolio? The Zacks Style Scores can help you with that.

Exploring Analyst Estimates for Pfizer (PFE) Q4 Earnings, Beyond Revenue and EPS
Exploring Analyst Estimates for Pfizer (PFE) Q4 Earnings, Beyond Revenue and EPS
Exploring Analyst Estimates for Pfizer (PFE) Q4 Earnings, Beyond Revenue and EPS
PFE
zacks.com30 January 2025

Instead of just focusing on Wall Street's predictions for Pfizer's (PFE) earnings, let's explore some important metrics to better understand how the company might perform in the quarter that ends in December 2024. This will give us a clearer picture of its potential.

Is Pfizer Inc. (PFE) the Safe Stock to Buy for the Long Term in 2025?
Is Pfizer Inc. (PFE) the Safe Stock to Buy for the Long Term in 2025?
Is Pfizer Inc. (PFE) the Safe Stock to Buy for the Long Term in 2025?
PFE
Insider Monkey29 January 2025

We have just released a list of 12 Safe Stocks to Invest in for the Long Term in 2025. In this article, we will examine how Pfizer Inc. (NYSE:PFE) compares to other safe stocks for long-term investment in 2025. The US stock market is frequently seen as one of […]

Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
PFE
seekingalpha.com28 January 2025

Before the earnings report next Tuesday, Pfizer appears to be undervalued at its current price of $26.55 and a valuation of $150 billion. However, it might be unrealistic to expect a significant increase in value. My discounted cash flow analysis indicates the stock should be worth around $50, but this relies on the company successfully launching new products, improving operations, and reducing debt. Pfizer's management emphasizes their goals of enhancing research and development, increasing profit margins, achieving commercial success, and optimizing capital use to boost shareholder value by 2025.

I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.
I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.
I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.
PFE
Motley Fool28 January 2025

When combined with reinvesting dividends, high-yield dividend stocks have shown impressive results compared to the S&P 500 over more than 20 years. Companies that consistently offer high dividend yields usually have certain important traits. AbbVie Inc. (NYSE: ABBV) is my main investment in the healthcare industry.

PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor
PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor
PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor
PFE
zacks.com28 January 2025

A Bloomberg article indicates that activist investor Starboard has decided not to nominate any directors to Pfizer's board this year, showing some leniency towards the company.

Here's How to Play Pfizer Stock Before Q4 Earnings Release
Here's How to Play Pfizer Stock Before Q4 Earnings Release
Here's How to Play Pfizer Stock Before Q4 Earnings Release
PFE
zacks.com28 January 2025

PFE's growth in the fourth quarter is probably due to its non-COVID medications and the impact of new and recently acquired products.

Pfizer's Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In Colorectal Cancer Patients
Pfizer's Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In Colorectal Cancer Patients
Pfizer's Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In Colorectal Cancer Patients
PFE
benzinga.com27 January 2025

On Saturday, Pfizer Inc. announced the findings from the Phase 3 BREAKWATER trial. This trial looked at the effectiveness of Braftovi (encorafenib) when used together with cetuximab (known as Erbitux) and mFOLFOX6 (which includes fluorouracil, leucovorin, and oxaliplatin) in patients suffering from metastatic colorectal cancer (mCRC) with a BRAF V600E mutation.

FAQ

  • What is the primary business of Pfizer?
  • What is the ticker symbol for Pfizer?
  • Does Pfizer pay dividends?
  • What sector is Pfizer in?
  • What industry is Pfizer in?
  • What country is Pfizer based in?
  • When did Pfizer go public?
  • Is Pfizer in the S&P 500?
  • Is Pfizer in the NASDAQ 100?
  • Is Pfizer in the Dow Jones?
  • When was Pfizer's last earnings report?
  • When does Pfizer report earnings?
  • Should I buy Pfizer stock now?

What is the primary business of Pfizer?

Pfizer Inc. is one of the leading international biopharmaceutical companies, founded in New York in 1849. Every year, Pfizer's medicines and vaccines help people around the world fight many diseases and lead a healthy lifestyle. The company's product portfolio includes medicines, including vaccines, as well as well-known vitamins and other products that promote health maintenance. The IH segment focuses on the development and commercialization of medicines and vaccines for internal diseases, oncology, inflammation and immunology, morbidity, and healthcare. The EH segment is involved in the development and supply of proprietary generics, non-patented sterile injectable drugs, biosimilars, and certain proprietary products, including anti-infectives.

What is the ticker symbol for Pfizer?

The ticker symbol for Pfizer is NYSE:PFE

Does Pfizer pay dividends?

Yes, Pfizer pays dividends. The last payment was $0.43, with an ex-dividend date on 24 January 2025

What sector is Pfizer in?

Pfizer is in the Healthcare sector

What industry is Pfizer in?

Pfizer is in the Drug Manufacturers - General industry

What country is Pfizer based in?

Pfizer is headquartered in United States

When did Pfizer go public?

Pfizer's initial public offering (IPO) was on 01 June 1972

Is Pfizer in the S&P 500?

Yes, Pfizer is included in the S&P 500 index

Is Pfizer in the NASDAQ 100?

No, Pfizer is not included in the NASDAQ 100 index

Is Pfizer in the Dow Jones?

No, Pfizer is not included in the Dow Jones index

When was Pfizer's last earnings report?

Pfizer's most recent earnings report was on 17 January 2025

When does Pfizer report earnings?

The next expected earnings date for Pfizer is 1 May 2025

Should I buy Pfizer stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions